P-9600 Paclitaxel, >99.5%

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; soluble in ethanol at 40 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

ASM-127 ASM-126 ASM-125 ASM-124 ASM-123 ASM-122 ASM-121 ASM-120 ASM-119 ASM-118 ASM-117 ASM-116 ASM-115 ASM-114 ASM-113 ASM-112 ASM-111 ASM-110 ASM-109 ASM-108

View the SDS for this product

• More than 1,250 labs worldwide have purchased Paclitaxel from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
• Antitumor and antileukemic agent originally isolated in 1971 from the bark of the yew tree, Taxus brevifolia. Wani, M.C., et al. "Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia." J. Am. Chem. Soc. 93: 2325-2327 (1971). McGuire, W.P., et al. "Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms" Ann. Int. Med. 111: 273-279 (1989).
• Binds to β-tubulin and promotes the assembly of microtubules that resist depolymerization preventing normal cell division. Rowinsky, E.K., et al. "Taxol: a novel investigational antimicrotubule agent." J. Natl. Cancer Inst. 82: 1247-1259 (1990). Parekh, H. and Simpkins, H. "The transport and binding of taxol." Gen. Pharmacol. 29: 167-172 (1997). Jordan, A., et al. "Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle investigational antimicrotubule agent." Med. Res. Rev. 18: 259-296 (1998).
• Paclitaxel is the active ingredient in the drug product sold under the trade names Abraxane® and Taxol®. This drug is currently approved in at least one country for use in patients with advanced carcinoma of the ovary and/or breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.. NOTE: THE PACLITAXEL SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ABRAXANE® or TAXOL®, AND IS NOT FOR HUMAN USE.
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
• Induces apoptosis through a JNK-dependent pathway in the early phase followed by a JNK-independent pathway that results in Bcl-2 phosphorylation. Wang, T.H., et al. "Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-termnial kinase (JNK)-dependent and -independent pathways in overian cancer cells." J. Biol. Chem. 274: 8208-8216 (1999). Shtil, A.A., et al. "Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells." Oncogene 18: 377-384 (1999). Srivastava, R.K., et al. "Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase." Mol. Cell. Biol. 18: 3509-3517 (1998). Torres, K., and Horwitz, S.B. "Mechanisms of Taxol-induced cell death are concentration dependent." Cancer Res. 58: 3620-3626 (1998).